과민성 방광 치료 시장 : 치료법별, 질환별, 최종사용자별, 지역별

Overactive Bladder Treatment Market is estimated to be valued at USD 4.82 Bn in 2026 and is expected to reach USD 7.91 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.3% from 2026 to 2033.

Overactive bladder (OAB) is a long-term bladder condition in which people suffer with symptoms such as a sudden release of urine, peeing more often than usual, sleep disturbance due to peeing during the night and, in some cases, accidental urine leakage. The disease has a major impact on quality of life and is becoming more common in many countries due to an aging populace and growing awareness of bladder health.

The overactive bladder treatment market comprises of drugs, neuromodulation options, botulinum toxin treatments and various surgical options. With continuous improvements in the medicine, mini-invasive surgical and neuromodulation techniques, the market is expected to show increasing success stories. Increasing healthcare expenditure and early awareness campaigns is contributing favorably to this market.

Market Dynamics

The global overactive bladder treatment market is driven by increasing rate of overactive bladder, urinary incontinence and the expanding aging demographic. Rising Incidence rate of obesity and diabetes, improving diagnosis and deepening knowledge of the bladder incontinence issues among patients continues to promote the growth of overactive bladder market. Alongside the development of applications for beta-3 adrenergic agonists, neuromodulation and several other minimally invasive techniques continue to enlarge the scope of available therapeutic options.

However, a number of constraints are present in the market, such as negative side effects associated with anticholinergic therapies, high costs and relatively poor reimbursement coverage. Additionally, social stigma and underreporting of bladder problems prevent timely diagnosis and treatment. Nevertheless, new and expanding emerging economies, digital health modalities, new drug delivery mediums and advancements in overactive bladder therapies will offer new opportunities for growth in the overactive bladder treatment market.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global overactive bladder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Astellas Pharma Inc., Pfizer Inc., AbbVie Inc., Sumitomo Pharma Co., Ltd., Urovant Sciences GmbH, Teva Pharmaceutical Industries Ltd., Zydus Lifesciences Limited, Viatris Inc., Medtronic plc, and Laborie Medical Technologies
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global overactive bladder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global overactive bladder treatment market

Market Segmentation

• Treatment Type Insights (Revenue, USD Bn, 2021 - 2033)
• Pharmacological Treatment
• Neuromodulation Therapy
• Botulinum Toxin Injections
• Behavioral Therapy
• Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
• Overactive Bladder Wet
• Overactive Bladder Dry
• End User Insights (Revenue, USD Bn, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Astellas Pharma Inc.
• Pfizer Inc.
• AbbVie Inc.
• Sumitomo Pharma Co., Ltd.
• Urovant Sciences GmbH
• Teva Pharmaceutical Industries Ltd.
• Zydus Lifesciences Limited
• Viatris Inc.
• Medtronic plc
• Laborie Medical Technologies

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Overactive Bladder Treatment Market, By Treatment Type
  • Global Overactive Bladder Treatment Market, By Disease Type
  • Global Overactive Bladder Treatment Market, By End User
  • Global Overactive Bladder Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Industry Trends

4. Global Overactive Bladder Treatment Market, By Treatment Type, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Pharmacological Treatment
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Neuromodulation Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Botulinum Toxin Injections
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Behavioral Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Overactive Bladder Treatment Market, By Disease Type, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Overactive Bladder Wet
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Overactive Bladder Dry
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Overactive Bladder Treatment Market, By End User, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Ambulatory Surgical Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Overactive Bladder Treatment Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Astellas Pharma Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sumitomo Pharma Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Urovant Sciences GmbH
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Zydus Lifesciences Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Medtronic plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Laborie Medical Technologies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us